Results 61 to 70 of about 7,348 (201)
Mesalamine induced hepatotoxicity. Is mesalamine safe?
Revista Española de Enfermedades DigestivasDear Editor: Mesalamine is a medication used widely in the treatment of patients with inflammatory bowel disease. Although mesalamine is considered safe, hepatotoxicity has been reported with an incidence of 0-4%. We present the clinical picture of a patient with hepatotoxicity due to mesalamine.
Javier, Pérez-Valenzuela +3 more
openaire +2 more sources
Mesalamine-induced myocarditis following diagnosis of Crohn's disease: A case report
Revista Portuguesa de Cardiologia, 2013 Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. We present the case of a 19-year-old male who developed chest pain two weeks after beginning mesalamine ...
Carlos Galvão Braga +7 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, Volume 62, Issue 9, Page 877-886, November 2025.No significant differences were found in adherence or relapse of either a single 5‐ASA tablet or three‐tablet treatment. The simplified single‐tablet lower dose treatment could be a feasible alternative to the conventional three‐tablet regimen. ABSTRACT Background 5‐Aminosalicylate (5‐ASA) is recommended for the treatment of mild‐to‐moderate ulcerative
Rie Louise Møller Nordestgaard +11 more
wiley +1 more source
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
Drug Design, Development and Therapy, 2011 Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first ...
Lilliana Oliveira, Russell D Cohen
doaj
Not Your Typical Ulcerative Colitis Patient [PDF]
Modern MedicineBackground: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD.
Teodora SPATARU +3 more
doaj +1 more source
A novel pH–enzyme-dependent mesalamine colon-specific delivery system
Drug Design, Development and Therapy, 2016 Lei Jin, Yi-cun Ding, Yu Zhang, Xiao-qing Xu, Qin Cao Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China Abstract: The aim of the present study was to ...
Jin L, Ding Y, Zhang Y, Xu X, Cao Q
doaj
Avicenna Journal of Medicine, 2012 Inflammatory bowel disease and its various treatments may affect the kidney in several ways. Recently, case reports have been published documenting the development of nephrotic syndrome after the treatment for inflammatory bowel disease with 5 ...
Belal M Firwana +6 more
doaj +1 more source
Clinical and Experimental Gastroenterology, 2009 Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj
Simple one-pot green method for large-scale production of mesalamine, an anti-inflammatory agent
Green Processing and Synthesis, 2019 We report a rapid and efficient synthesis protocol for mesalamine via a green approach with 2-chloro-5-nitrobenzoic acid as the starting material, for its large-scale production.
Vijaya Lakshmi C. +2 more
doaj +1 more source
Myopericarditis in a patient with ulcerative colitis treated with mesalamine—Case report and review of the literature [PDF]
, 2014 Marta Roczek +3 more
openalex +1 more source